<p>Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.</p>

Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.

Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.

Share Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Sign up to save your podcasts

Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer

More shows like Breast Cancer Update

JAMA Editors' Summary

NEJM This Week

JAMA Clinical Reviews

Lung Cancer Update

Hematologic Oncology Update

Prostate Cancer Update

Gastrointestinal Cancer Update

Gynecologic Oncology Update

Dermatologic Oncology Update

Research To Practice | Oncology Videos

ASCO Daily News

Mayo Clinic Talks

The Curbsiders Internal Medicine Podcast

The ONS Podcast

The Clinical Problem Solvers

Oncology Today with Dr Neil Love

Two Onc Docs

Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing